Platelet hyperaggregability, blood prostacyclin and dipyridamole

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Prostacyclin (PGI2) is a potent vasodilator and inhibitor of platelet aggregation.
• Understanding PGI2's role in blood is crucial for cardiovascular health.
• Platelet retention tests are used to assess thrombotic risk.

Purpose of the Study:

• To demonstrate the presence and influence of PGI2 in blood.
• To investigate the relationship between PGI2, erythrocyte properties, and dipyridamole.
• To identify factors contributing to persistent platelet hyperaggregability in treated patients.

Main Methods:

• Analysis of PGI2 levels in blood samples.
• Evaluation of platelet retention tests.
• Assessment of erythrocyte deformability and ATP reserve.
• Dosing studies with dipyridamole.

Main Results:

• PGI2 presence in blood influences platelet retention tests.
• Erythrocyte ATP reserve and deformability correlate with PGI2 presence on erythrocyte sites.
• Dipyridamole dosage increases PGI2 site load, with saturation at 450 mg daily.
• Approximately 10% of dipyridamole-treated atherosclerosis patients exhibit persistent platelet hyperaggregability and low PGI2 levels.

Conclusions:

• PGI2 plays a role in platelet retention, mediated by erythrocyte interactions.
• Erythrocyte health is critical for maintaining adequate PGI2 levels.
• Dipyridamole effectively increases PGI2 binding sites up to a certain dose.
• A subset of patients may not achieve sufficient PGI2 levels or platelet function normalization despite treatment.